313 related articles for article (PubMed ID: 36224603)
1. Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial.
Huang X; Liu Q; Zhong G; Peng Y; Liu Y; Liang L; Hong H; Feng W; Yang S; Zhang Y; Xian S; Li Z; Zhou Y; Zhang Z; Jiang W; Liang J; Liu ZG
J Exp Clin Cancer Res; 2022 Oct; 41(1):300. PubMed ID: 36224603
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial.
Zhang Z; Wu B; Peng G; Xiao G; Huang J; Ding Q; Yang C; Xiong X; Ma H; Shi L; Yang J; Hong X; Wei J; Qin Y; Wan C; Zhong Y; Zhou Y; Zhao X; Leng Y; Zhang T; Wu G; Yao M; Zhang X; Yang K
Clin Cancer Res; 2022 Aug; 28(15):3268-3276. PubMed ID: 35766967
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial.
Wu D; Li Y; Xu P; Fang Q; Cao F; Lin H; Li Y; Su Y; Lu L; Chen L; Li Y; Zhao Z; Hong X; Li G; Tian Y; Sun J; Yan H; Fan Y; Zhang X; Li Z; Liu X
Nat Commun; 2024 Mar; 15(1):2177. PubMed ID: 38467604
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer.
Xu X; Sun Z; Liu Q; Zhang Y; Shen L; Zhang C; Lin H; Hu B; Rong L; Chen H; Wang X; Zhao X; Bai YR; Ye Q; Ma X
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458635
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
6. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
7. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial).
Huang Y; Sun J; Li J; Zhu D; Dong M; Dou S; Tang Y; Shi W; Sun Q; Zhao T; Zhou Z; Zhou X; Liu Y; Li J; Zhu G; Zhang D; Chen Y; Zhu Q; Ju W; Zhong L
Int J Surg; 2023 Aug; 109(8):2220-2227. PubMed ID: 37288582
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).
Yang Y; Zhang J; Meng H; Ling X; Wang X; Xin Y; Jiang H; Zhang L; Fang C; Liang H; Ma J; Zhu J
Int J Surg; 2024 Mar; 110(3):1430-1440. PubMed ID: 38051925
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
[TBL] [Abstract][Full Text] [Related]
11. [Phase Ⅱ clinical trial of PD-1 inhibitor combined with chemotherapy for locally advanced resectable oral squamous cell carcinoma].
Wang HL; Yue K; Wu YS; Duan YS; Jing C; Wang XD
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):335-342. PubMed ID: 38599641
[No Abstract] [Full Text] [Related]
12. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
He W; Leng X; Mao T; Luo X; Zhou L; Yan J; Peng L; Fang Q; Liu G; Wei X; Wang K; Wang C; Zhang S; Zhang X; Shen X; Huang D; Yi H; Bei T; She X; Xiao W; Han Y
Oncologist; 2022 Feb; 27(1):e18-e28. PubMed ID: 35305102
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
Ferris RL; Spanos WC; Leidner R; Gonçalves A; Martens UM; Kyi C; Sharfman W; Chung CH; Devriese LA; Gauthier H; Chiosea SI; Vujanovic L; Taube JM; Stein JE; Li J; Li B; Chen T; Barrows A; Topalian SL
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083421
[TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.
Zhu X; Sun L; Song N; He W; Xie B; Hu J; Zhang J; Yang J; Dai J; Bian D; Xia H; Sun F; Xiong A; Luo J; Zhang L; Yu H; Liu M; Liu H; Wang H; Zhang H; Chen C; Wu C; Duan L; Zhu Y; Zhang P; Jiang G
BMC Med; 2022 Dec; 20(1):493. PubMed ID: 36581917
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant sintilimab plus chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase II clinical trial (CY-NICE).
Chen Y; Ren M; Li B; Meng Y; Wang C; Jiang P; Song T; Yang J; Zhu D; Yu Q
J Thorac Dis; 2023 Dec; 15(12):6761-6775. PubMed ID: 38249875
[TBL] [Abstract][Full Text] [Related]
16. Toripalimab combined with docetaxel and cisplatin neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a single-center, single-arm clinical trial (ESONICT-2).
Gao L; Lu J; Zhang P; Hong ZN; Kang M
J Gastrointest Oncol; 2022 Apr; 13(2):478-487. PubMed ID: 35557591
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real-world retrospective study.
Wu WJ; Liu Q; An PG; Wang L; Zhang JY; Chen Y; Zhang T; Zhang J
Front Immunol; 2023; 14():1282629. PubMed ID: 38035079
[TBL] [Abstract][Full Text] [Related]
18. Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC.
Li Y; Zhou A; Liu S; He M; Chen K; Tian Z; Li Y; Qin J; Wang Z; Chen H; Tian H; Yu Y; Qu W; Xue L; He S; Wang S; Bie F; Bai G; Zhou B; Yang Z; Huang H; Fang Y; Li B; Dai X; Gao S; He J
BMC Med; 2023 Mar; 21(1):86. PubMed ID: 36882775
[TBL] [Abstract][Full Text] [Related]
19. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE).
Yan X; Duan H; Ni Y; Zhou Y; Wang X; Qi H; Gong L; Liu H; Tian F; Lu Q; Sun J; Yang E; Zhong D; Wang T; Huang L; Wang J; Chaoyang Wang ; Wang Y; Wan Z; Lei J; Zhao J; Jiang T
Int J Surg; 2022 Jul; 103():106680. PubMed ID: 35595021
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant PD-1/PD-L1 axis blockade for patients with head and neck squamous cell carcinoma.
Huang S; Xiong C; Tan K
Am J Otolaryngol; 2023; 44(6):103985. PubMed ID: 37442083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]